BioVox is an online life sciences news platform, established to help spread the news about Belgian innovation both inside the country and around the world. With a local focus and a global reach, BioVox is more than just a news platform: it is a community – a growing global network that spans academia, industry, and finance. With a finger on the pulse of the latest Belgian breakthroughs and topics, BioVox collects the best stories and insights in the free monthly newsletter, sent to over 10,000 subscribers around the world. BioVox has an important role to play in raising recognition for the activities of this thriving region, but also in bringing the community together. As media partner and organizer of science events, BioVox helps facilitating collaborations between researchers, industry leaders, investors, and policymakers.  

In recent years, Belgium has firmly established itself as a frontrunner in biotech. Strong biotech clusters have emerged in multiple Belgian hubs, including Ghent, Charleroi, Leuven, and Liège. These clusters are hotspots for collaboration between world-class universities, research centers, hospitals, start-ups, SMEs, and large international companies. The cross-pollination in this fertile ecosystem has led to exceptional local expertise, especially in technologies such as messenger RNA (mRNA), plasmid DNA, cell and gene therapy, and monoclonal and polyclonal antibodies.

The health and biotech industries are already vitally important to the Belgian economy and workforce. The country currently ranks third in the EU for biopharmaceutical exports, with a total of €56 billion generated in 2020. Belgian biotech and pharma companies directly employ more than 40,000 people – twice the European average – and many more indirectly.